iRadimed Corp Q2 2025 Earnings: Revenue Hits $20.4 Million, Surpasses Estimate, GAAP EPS at $0.45

iRadimed Corp reported Q2 2025 revenue of $20.4 million, surpassing the analyst estimate of $20.01 million. The company's GAAP diluted EPS reached $0.45, exceeding the estimated EPS of $0.40. iRadimed Corp's financial achievements include a record GAAP diluted EPS of $0.45, an 18% increase compared to Q2 2024. The company anticipates operational inefficiencies in Q3 2025 due to the transition to a new facility. Despite this, iRadimed Corp is expected to drive sustained growth with its expanded capacity and new product commercialization.

iRadimed Corp (NASDAQ: IRMD) announced its financial results for the second quarter of 2025, showcasing robust performance and record earnings. The company reported revenue of $20.4 million, surpassing the analyst estimate of $20.01 million. The GAAP diluted EPS reached $0.45, exceeding the estimated EPS of $0.40.

The company's GAAP diluted EPS of $0.45 represents an 18% increase compared to the same period in 2024. This strong performance was driven by increased revenue from MRI compatible IV infusion pump systems and patient vital signs monitoring systems, which saw a 14% increase year-over-year. The gross profit margin for the quarter remained steady at 78%.

Despite the strong results, iRadimed Corp anticipates some operational inefficiencies in the third quarter of 2025 due to the transition to its new facility in Orlando, Florida. However, the company remains optimistic about its growth trajectory, expecting the expanded capacity and commercialization of its next-generation MRI-compatible IV infusion pump to drive sustained growth.

For the third quarter of 2025, iRadimed Corp expects revenue of $20.5 million to $20.9 million, with GAAP diluted earnings per share of $0.41 to $0.45, and non-GAAP diluted earnings per share of $0.45 to $0.49. The company has also raised its full-year 2025 revenue guidance to $80.0 million to $82.5 million, with GAAP diluted earnings per share of $1.60 to $1.70, and non-GAAP diluted earnings per share of $1.76 to $1.86.

The company's board of directors declared a regular quarterly cash dividend of $0.17 per share of common stock, payable on August 28, 2025.

References:

[1] https://www.globenewswire.com/news-release/2025/08/01/3125764/32443/en/IRADIMED-CORPORATION-Reports-Record-Second-Quarter-2025-Financial-Results.html